Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.30
-0.0200-0.60%
Post-market: 3.300.00000.00%19:41 EDT
Volume:707.42K
Turnover:2.36M
Market Cap:625.32M
PE:-7.74
High:3.41
Open:3.34
Low:3.29
Close:3.32
Loading ...

Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Yesterday

Strategic Legal Maneuvers Bolster Buy Rating for Arbutus Biopharma Amid Global Patent Challenges

TIPRANKS
·
04 Mar

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

MT Newswires Live
·
03 Mar

Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech

THOMSON REUTERS
·
03 Mar

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

THOMSON REUTERS
·
03 Mar

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

GlobeNewswire
·
03 Mar

Positive Outlook on Arbutus Biopharma Amid Strategic Focus and Legal Developments

TIPRANKS
·
27 Feb

Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board

MT Newswires Live
·
25 Feb

Arbutus Biopharma's Entire Board Replaced as New CEO Steps In

Dow Jones
·
25 Feb

Arbutus Biopharma appoints Lindsay Androski as CEO

TIPRANKS
·
25 Feb

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - Appoints Lindsay Androski as CEO

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - All Existing Arbutus Board Members Step Down

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - to Pause Investor Meetings During Strategic Review

THOMSON REUTERS
·
25 Feb

Press Release: Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Dow Jones
·
25 Feb

Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
24 Feb